Jun 16, 2026 07:31AM
Jun 16, 2026 07:30AM
Jun 1, 2026 07:30AM
May 21, 2026 07:30AM
May 21, 2026 07:30AM
May 14, 2026 07:31AM
May 14, 2026 07:30AM Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
May 7, 2026 04:15PM
Mar 31, 2026 04:31PM
Mar 31, 2026 04:30PM
Mar 26, 2026 07:31AM
Mar 26, 2026 07:30AM
Mar 17, 2026 07:31AM
Mar 17, 2026 07:30AM Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026
Mar 2, 2026 07:31AM
Mar 2, 2026 07:30AM
Feb 5, 2026 07:31AM
Feb 5, 2026 07:30AM
Jan 27, 2026 07:31AM
Jan 27, 2026 07:30AM
Jan 6, 2026 07:30AM Cognition Therapeutics publishes Phase 2 results for DLB treatment
Jan 6, 2026 07:30AM
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM
Dec 1, 2025 07:31AM
Dec 1, 2025 07:30AM
Nov 6, 2025 07:30AM
Aug 12, 2025 04:00PM Cognition Therapeutics aligns with FDA on Phase 3 trial design for alzheimer's drug
Aug 12, 2025 04:00PM
Aug 7, 2025 04:00PM
Jul 29, 2025 07:30AM
Jul 21, 2025 07:31AM
Jul 21, 2025 07:30AM
Jul 16, 2025 07:31AM
Jul 16, 2025 07:30AM Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Jul 14, 2025 07:07AM
Jul 10, 2025 07:31AM
Jul 10, 2025 07:30AM
Jun 26, 2025 06:45AM
Jun 25, 2025 07:30AM
May 7, 2025 07:30AM
Mar 24, 2025 06:42AM Cognition Therapeutics (CGTX) PT Lowered to $5 at H.C. Wainwright
Mar 20, 2025 07:00AM
Feb 26, 2025 07:00AM
Feb 26, 2025 07:00AM
Jan 8, 2025 04:14PM
Dec 18, 2024 07:23AM
Dec 18, 2024 07:22AM
Nov 25, 2024 07:30AM Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population
Nov 13, 2024 07:30AM

323,584 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All